Hot Life Science Investor Mandate 3: Chinese Venture Capital Firm Seeking mHealth, Gene Sequencing, Immunotherapy, Stem cells, and Antibody Therapeutics

18 Dec

A venture capital firm based in China makes early-growth stage investments in the life science sector, preferably in series A and B; the firm may also consider series C opportunities. The firm typically invests RMB 100 million (USD 16 million) or more per company. The firm prefers to invest in companies based in China, but is open to outstanding opportunities from around the globe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is most interested in mHealth, gene sequencing, immunotherapy, stem cells, and antibody therapeutics. The firm is indication agnostic. The firm is also opportunistic to other cutting edge technologies in the healthcare industry. The firm is open to investing in companies in the pre-clinical phase of development as well as those that have clinical data.

The firm seeks a strong and experienced management team and generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: